company background image
0QCO logo

Pharming Group LSE:0QCO Stock Report

Last Price

€0.73

Market Cap

€501.3m

7D

-0.9%

1Y

-31.0%

Updated

12 Nov, 2024

Data

Company Financials +

0QCO Stock Overview

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

0QCO fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Pharming Group N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pharming Group
Historical stock prices
Current Share Price€0.73
52 Week High€1.22
52 Week Low€0.65
Beta0.81
11 Month Change-6.22%
3 Month Change3.28%
1 Year Change-31.02%
33 Year Change-7.20%
5 Year Change-39.76%
Change since IPO-92.68%

Recent News & Updates

Recent updates

Shareholder Returns

0QCOGB BiotechsGB Market
7D-0.9%-3.6%-0.8%
1Y-31.0%-15.2%7.9%

Return vs Industry: 0QCO underperformed the UK Biotechs industry which returned -15.2% over the past year.

Return vs Market: 0QCO underperformed the UK Market which returned 7.9% over the past year.

Price Volatility

Is 0QCO's price volatile compared to industry and market?
0QCO volatility
0QCO Average Weekly Movement6.0%
Biotechs Industry Average Movement8.8%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.0%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0QCO has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0QCO's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988382Simon de Vrieswww.pharming.com

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group N.V. Fundamentals Summary

How do Pharming Group's earnings and revenue compare to its market cap?
0QCO fundamental statistics
Market cap€501.30m
Earnings (TTM)-€16.78m
Revenue (TTM)€269.09m

1.8x

P/S Ratio

-29.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QCO income statement (TTM)
RevenueUS$285.75m
Cost of RevenueUS$30.30m
Gross ProfitUS$255.44m
Other ExpensesUS$273.26m
Earnings-US$17.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.026
Gross Margin89.39%
Net Profit Margin-6.24%
Debt/Equity Ratio42.3%

How did 0QCO perform over the long term?

See historical performance and comparison